Published in Managed Care Business Week, October 12th, 2004
The team injected adult bone marrow-derived stem cells from mice or humans into the back of mouse eyes at an appropriate stage of development and these injections dramatically curtailed retinal degeneration. In the published article, the team shows that the treated eyes of the mice, when compared to the fellow untreated eyes, had a completely normal retinal vasculature, had significantly improved retinal tissue, and responded to light.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.